Aastrom raises $5 million for commercialisation:
This article was originally published in Clinica
Executive Summary
Aastrom Bioscienceshas raised $5 million in a private placement to a single investor, in order to begin the commercialisation of its AastromReplicell cell production system and commence of trials in the US. The funding will allow the Ann Arbor, Michigan-based company to begin production-stage manufacture of the stem cell replication system which will be used to increase blood and immune system function for cancer and blood disease patients.